

Resource Summary Report

Generated by PRECISE-TBI on Jul 31, 2026

Amorfix

RRID:SCR_003783

Type: Tool

Proper Citation

Amorfix (RRID:SCR_003783)

Resource Information

URL: <http://www.amorfix.com/>

Proper Citation: Amorfix (RRID:SCR_003783)

Description: Product development company focused on therapeutic products and diagnostic devices targeting misfolded protein diseases. On July, 2015 the company name was changed to ProMIS Neurosciences, Inc.

Abbreviations: AMF

Synonyms: Amorfix Life Science, Amorfix Life Sciences Ltd., Amorfix Life Sciences, ProMIS Neurosciences

Resource Type: commercial organization

Keywords: diagnostic, therapy, alzheimer, protein, misfolded protein disease

Related Condition: Alzheimer's disease, Amyotrophic Lateral Sclerosis, Cancer

Resource Name: Amorfix

Resource ID: SCR_003783

Alternate IDs: Crossref funder ID: 100007611, nlx_158072, grid.422608.a

Alternate URLs: <https://ror.org/045rtab03>

Record Creation Time: 20220129T080220+0000

Record Last Update: 20260725T190542+0000

Ratings and Alerts

No rating or validation information has been found for Amorfix.

No alerts have been found for Amorfix.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Pataer A, et al. (2020) Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells. *Oncogene*, 39(4), 801.

, et al. (2005) Corporate Activity - Mergers and Acquisition. *Pharmaceutical & diagnostic innovation*, 3(10), 18.